Bhamidipati, Deepak
Verma, Anuj
Sui, Dawen
Maru, Dipen
Mathew, Grace
Lang, Wenhua
Posadas, Juan
Hein, Joshua
Kopetz, Scott
Futreal, Andrew
Wistuba, Ignacio I.
Gupta, Sanjay
Lee, J. Jack http://orcid.org/0000-0001-5469-9214
Overman, Michael J.
Tam, Alda L.
Funding for this research was provided by:
The University of Texas MD Anderson Cancer Center Moon Shots Programâ„¢
Article History
Received: 19 May 2021
Accepted: 22 September 2021
First Online: 27 October 2021
Competing interests
: M.O. has received honoraria from Roche, Bristol Meyers Squibb, Medimmune, and Celgene, and has served as a consultant or adviser to Roche, Bristol Meyers Squibb, Medimmune, Merck, and Amgen. A.T. has received research funding from Boston Scientific and Guerbet and has served as a consultant or adviser to Boston Scientific and Cello Therapeutics, Inc. I.W. reports grants and personal fees from Genentech/Roche, Bayer, Bristol-Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Merck, GlaxoSmithKline, Guardant Health, and MSD; grants from Oncoplex, DepArray, Adaptive, Adaptimmune, EMD Serono, Takeda, Amgen, Karus, Johnson & Johnson, Iovance, 4D, Novartis, Oncocyte, and Akoya; personal fees from Flame. The remaining authors declare no competing interests.